Suitable aromatic amine containing biologically active moieties D are, for example, ( )-Carbovir, ( )-Hymenin, ( )-Norcisapride, ( )-Picumeterol, (R)-Aminoglutethimide, (R)-Clenbuterol, (S)-Aminoglutethimide, (S)-Clenbuterol, [6-p-aminophenylalanine]-angiotensin II, 10-Demethoxystreptonigrin, 17-Aminogeldanamycin, 1-Aminoacridine, 1-Deazaadenine, 1-NA-PP 1, 1-NM-PP 1, 2,7-Diaminoacridine, 2,7-Dimethylproflavine, 2-Amino-6(5H)-phenanthridinone, 2-Aminoacridine, 2-amino-Carbanilide, 2-Aminohistamine, 2-Aminoperimidine, 2- suitable drugs with aromatic amine groups may be selected from the list containing ( )-Draflazine, ( )-Indocarbazostatin B, (+)-(R)-Pramipexole, (R)-(+)-Terazosin, (R)-Ganciclovir Cyclic Phosphonate, (R)-Sufinosine, (R)-Zacopride, (S)-Sufinosine, (S)-Zacopride Hydrochloride, 17-Aminogeldanamycin, 2-Aminoaristeromycin, 2-Aminoneplanocin A, 3-Chloroprocainamide, 3-Deazaadenosine, 4-Aminosalicylic Acid, 4-Chlorophenylthio-DADME-Immucillin-A, 5-Homoneplanocin A, 5-Aminosalicylic Acid, 9-Aminocamptothecin, Abacavir Succinate, Abaca Suitable drugs with an amine group may be selected from the group consisting of Aphidicolin Glycinate, Cetrorelix Acetate, Picumeterol Fumarate, ( )-Draflazine, ( )-Indocarbazostatin B, (+)-(23,24)-Dihydrodiscodermolide, (+)-(R)-Pramipexole, (R)-(+)-Amlodipine, (R)-(+)-Terazosin, (R)-Ganciclovir Cyclic Phosphonate, (R)-Sufinosine, (R)-Zacopride, (S)-( )-Norketamine, (S)-Oxiracetam, (S)-Sufinosine, (S)-Zacopride Hydrochloride, [90Y]-DOTAGA-Substance P, [ARG(Me)9] MS-10, [D-TYR1,ARG(Me)9] MS-10 Suitable secondary amine-containing biologically active moieties may be selected from the group consisting of ( )-3-O-Acetylspectaline hydrochloride, ( )-3-O-tert-Boc-spectaline hydrochloride, ( )-Cicloprolol, ( )-Norchloro-[18F]fluoro-homoepibatidine, ( )-Salbutamol hydrochloride, ( )-Salmeterol, (+)-(S)-Hydroxychloroquine, (+)-Isamoltan, (+)-R-Pramipexole, (R)-(+)-Amlodipine, (R)-Clevidipine, (R)-NSP-307, (R)-Teludipine, (R)-Thionisoxetine, (S)-Clevidipine, (S)N-Desmethyltrimebutine, (S)-Noremop Suitable amine-containing biologically active moieties may also be selected from the group consisting of Fab (fragment, antigen-binding), F(ab)2 fragments, Fc (fragment, crystallizable), pFc fragment, Fv (fragment, variable), scFv (single-chain variable fragment), di-scFv/diabodies, bi-specific T-cell engager, CDRs (complementarity determining regions), single-domain antibodies (sdABs/Nanobodies), heavy chains ( , , , , ) or heavy chain fragments, light chains ( , ) or light chain fragments, VH fragments (variable region of the heavy chain), VL fragments (variable region of the light chain), VHH fragments, VNAR fragments, shark-derived antibody fragments and affinity scaffold proteins, Kunitz domain-derived affinity scaffold proteins, centyrin-derived affinity scaffold proteins, ubiquitin-derived affinity scaffold proteins, lipocalin-derived affinity scaffold proteins Suitable drugs containing aromatic hydroxyl groups are, for example, ( )-cis-Resorcylide, ( )-Indocarbazostatin B, ( )-Salmeterol, ( )-Subersic acid, (+)-alpha-Viniferin, (+)-Etorphine, (+)-Indocarbazostatin, (+)SCH-351448, (R)-Gossypol, (S)-(+)-Curcuphenol, (S)-Methylnaltrexone bromide, [8]-Gingerol, [Arg(Me)9] MS-10, [D-Tyr1,Arg(Me)9] MS-10, [D-Tyr1,AzaGly7,Arg(Me)9] MS-10, [D-Tyr1] MS-10, [psi[CH2NH]Tpg4]Vancomycin aglycon, [Trp19] MS-10, 13-Deoxyadria Suitable drugs with a hydroxyl group may be selected fromt the group consisting of ( )-(2R*,3R*,11bS*)-Dihydrotetrabenazine, ( )-(2R*,3S*,11bR*)-Dihydrotetrabenazine, ( )-2-(2-Bromohexadecanoyl)paclitaxel, ( )-4,5-Didemethoxypicropodophyllin, ( )-4-Demethoxypicropodophyllin, ( )-9-Dehydrogalanthaminium bromide, ( )-Calicheamicinone, ( )-Cicloprolol, ( )-cis-Resorcylide, ( )-Indocarbazostatin B, ( )-Kendomycin, ( )-Kolavenol, ( )-Salmeterol, ( )-Subersic Suitable drugs with carboxyl groups may be be selected from the list containing ( )-Subersic acid, (+)-Deoxoartelinic acid, (+)-Hemipalmitoylcarnitinium, (+)-Indobufen, (+)-SCH-351448, (E)-p-Coumaroylquinic acid, (Z)-Indenaprost, [111In-DTPA-Pro1,Tyr4]bombesin, [90Y]-DOTAGA-substance P, [psi[CH2NH]Tpg4]Vancomycin aglycon, 111In-Pentetreotide, 11-Keto-Beta-Boswellic Acid, 15-Methoxypinusolidic acid, 1-Methyl-D-tryptophan, 3,5-Dicaffeoylquinic acid, 3-MATIDA, 3-O-Acetyloleanolic acid, 4-Aminosalicylic acid, 6alpha-F Suitable drugs with a phosphate group may be selected fromt the group consisting of Adenophostin A, Adenophostin B, Atrinositol, Buflomedil pyridoxalphosphate, Cytostatin, Fludarabine phosphate, Fosfluconazole, Fosfonochlorin, Fosfosal, Fosopamine, Fosquidone, Fostamatinib, Ganciclovir monophosphate, Genistein-7-phosphate, Hydroxyphoslactomycin B, Leustroducsin A, Leustroducsin B, Leustroducsin C, Leustroducsin H, Mangafodipir trisodium, Menadiol sodium diphosphate, Miproxifene phosphate, Monophosphoryl lipid A, Phospholine, Phosphosalsalate, Pneumocandin B0 2-phosphate, Tafluposide, Triciribine phosphate, Ursolic acid phosphate
Symptoms may include sore throats, excessive phlegm, coughing, headaches and brain fog
Immediately after oral ingestion an increase in concentration of MC detected in expired air [103]
Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L
The free reconstitution calculator handles concentration math for each escalation step enter your vial size, BAC water volume, and current target dose, and the calculator outputs the exact syringe draw with a visual guide
PMID: 34676557 Purity & Documentation References Calculators Concentration (start) Volume (start) = Concentration (final) Volume (final)
